{"nctId":"NCT02505542","briefTitle":"Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo","startDateStruct":{"date":"2015-07","type":"ACTUAL"},"conditions":["Axial Spondyloarthrithis","Ankylosing Spondylitis"],"count":736,"armGroups":[{"label":"Open-label Certolizumab Pegol","type":"OTHER","interventionNames":["Biological: Certolizumab Pegol"]},{"label":"Double-blind Certolizumab Pegol 200 mg Q2W","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab Pegol"]},{"label":"Double-blind Certolizumab Pegol 200 mg Q4W","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab Pegol","Other: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Placebo to CZP 200 mg Q2W escape","type":"OTHER","interventionNames":["Biological: Certolizumab Pegol","Other: Placebo"]},{"label":"CZP 200 mg Q4W to CZP 200 mg Q2W escape","type":"OTHER","interventionNames":["Biological: Certolizumab Pegol","Other: Placebo"]},{"label":"CZP 200 mg Q2W to CZP 200 mg Q2W escape","type":"OTHER","interventionNames":["Biological: Certolizumab Pegol","Other: Placebo"]}],"interventions":[{"name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of adult-onset axial SpondyloArthritis (axSpA) with at least 3 months' symptom duration and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria for axSpA and symptom duration of less than 5 years prior to the participation of this study\n* Active disease at Screening as defined by\n\n  * Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥ 2.1\n  * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4\n  * Spinal pain \\> 4 on a 0 to 10 Numerical Rating Scale (NRS) (from BASDAI Item 2)\n  * for modified New York (mNY) -negative subjects only: C-reactive Protein (CRP) \\> upper limit of normal (ULN) and/or current evidence for sacroiliitis on the Screening Magnetic Resonance Imaging (MRI)\n* Inadequate response to, or contraindication to, or intolerant to at least 2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)\n\nExclusion Criteria:\n\n* Presence of total Spinal Ankylosis ('bamboo spine')\n* Diagnosis of any other Inflammatory Arthritis\n* Prior treatment with any experimental biological agents for treatment of Axial SpondyloArthritis (SpA)\n* Exposure to more than 1 TNF-antagonist or primary failure to TNF antagonist therapy\n* History of or current chronic or recurrent infections\n* High risk of infection\n* Recent live vaccination\n* Concurrent malignancy or a history of malignancy\n* Class III or IV congestive heart failure - New York Heart Association (NYHA)\n* Demyelinating disease of the central nervous system\n* Female subjects who are breastfeeding, pregnant or plan to become pregnant during the study or within 3 months following the last dose of the investigational product\n* Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in Part B Who Did Not Experienced a Flare","description":"A participant was considered to have experienced a flare if the participant had an Ankylosing spondylitis disease activity score (ASDAS) greater or equal to (≥) 2.1 at 2 consecutive visits or an ASDAS greater than (\\>) 3.5 at any visit during Part B up until Week 96.\n\nA participant qualified for Part B only if he achieved sustained remission after 48 weeks of Open-Label certolizumab pegol (CZP) treatment. Sustained remission was achieved when a participant had an ASDAS less than (\\<) 1.3 at Week 32 or Week 36 (if ASDAS \\< 1.3 at Week 32, it must have been \\< 2.1 at Week 36; if ASDAS \\< 2.1 at Week 32, it must have been \\< 1.3 at Week 36) and an ASDAS \\< 1.3 at Week 48.\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"83.7","spread":null},{"groupId":"OG002","value":"79.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Sustained Remission at Week 48 in Part A","description":"Sustained remission was achieved when a participant had an ASDAS less than (\\<) 1.3 at Week 32 or Week 36 (if ASDAS \\< 1.3 at Week 32, it must have been \\< 2.1 at Week 36; if ASDAS \\< 2.1 at Week 32, it must have been \\< 1.3 at Week 36) and an ASDAS \\< 1.3 at Week 48.\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) Disease Activity Categories at Week 48 in Part A","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nDisease activity was measured by categorical response variables:\n\n* ASDAS-Inactive Disease (ASDAS-ID): ASDAS \\< 1.3\n* ASDAS-Moderate Disease (ASDAS-MD): ASDAS ≥ 1.3, \\< 2.1\n* ASDAS-High Disease activity (ASDAS-HD): ASDAS ≥ 2.1, ≤ 3.5\n* ASDAS-very High Disease activity (ASDAS-vHD): ASDAS \\> 3.5\n\nMissing data were handled using last observation carried forward (LOCF) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) Clinical Improvement Categories at Week 48 in Part A","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nASDAS improvement was measured by binary response variables:\n\n* ASDAS-CII: ASDAS reduction (improvement) of ≥ 1.1 relative to Baseline\n* ASDAS-MI: ASDAS reduction (improvement) of ≥ 2.0 relative to Baseline\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Flare in Part B","description":"For those who met the criteria for flare (see primary efficacy variable), the time to flare was the length in days from randomization in Part B until the visit at which the criteria for flare were met. Participants who discontinued the study without meeting the criteria for flare were counted as experiencing a flare at the time of their last study visit.\n\nThe time to flare was analyzed using Kaplan-Meier methods. If Kaplan-Meier Estimate was NA for all estimates then more than 75 % failed to meet the flare condition.\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"371","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) Disease Activity Categories at Week 96 in Part B","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nDisease activity was measured by categorical response variables:\n\n* ASDAS-Inactive Disease (ASDAS-ID): ASDAS \\< 1.3\n* ASDAS-Moderate Disease (ASDAS-MD): ASDAS ≥ 1.3, \\< 2.1\n* ASDAS-High Disease activity (ASDAS-HD): ASDAS ≥ 2.1, ≤ 3.5\n* ASDAS-very High Disease activity (ASDAS-vHD): ASDAS \\> 3.5","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null},{"groupId":"OG001","value":"86.2","spread":null},{"groupId":"OG002","value":"69.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"13.8","spread":null},{"groupId":"OG002","value":"22.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) Clinical Improvement Categories at Week 96 in Part B","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nASDAS improvement was measured by binary response variables:\n\n* ASDAS-CII: ASDAS reduction (improvement) of ≥ 1.1 relative to Baseline\n* ASDAS-MI: ASDAS reduction (improvement) of ≥ 2.0 relative to Baseline\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"82.7","spread":null},{"groupId":"OG002","value":"75.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"67.3","spread":null},{"groupId":"OG002","value":"58.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society 20 % Response Criteria (ASAS20) Response at Week 96 in Part B","description":"The ASAS20 response was defined as an improvement of at least 20 % and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA), Pain assessment (total spinal pain NRS scores), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) and absence of deterioration in the potential remaining domain \\[deterioration was defined as a relative worsening of at least 20 % and an absolute worsening of at least 1 unit\\].\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"85.6","spread":null},{"groupId":"OG002","value":"78.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society 40 % Response Criteria (ASAS40) Response at Week 96 in Part B","description":"The ASAS40 response was defined as a relative improvement of at least 40 % and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA), Pain assessment (total spinal pain NRS scores), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) and no worsening at all in the remaining domain.\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"84.6","spread":null},{"groupId":"OG002","value":"73.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society (ASAS) 5/6 Response Criteria Response at Week 96 in Part B","description":"The ASAS 5/6 response was defined as achieving at least 20 % improvement in 5 of 6 domains, including the 4 domains defined for ASAS20 as well as spinal mobility (lateral spinal flexion) and C-reactive Protein (CRP).\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"70.2","spread":null},{"groupId":"OG002","value":"62.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society (ASAS) Partial Remission (PR) Response Criteria Response at Week 96 in Part B","description":"The ASAS partial remission (PR) response was defined as a score of ≤ 2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS20.\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"77.9","spread":null},{"groupId":"OG002","value":"70.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 96 in Part B","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nThere is a minimum score of 0.636 for the total ASDAS score, but no defined upper score. Based on the formula even in the situation that the CRP is normal, any value below 4 is recorded as \"below the limit of quantification\" (BLQ) and a value of BLQ/2=2 was prespecified. This assumption is triggering the lowest possible value of 0.636.\n\nThe change from Part B Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"0.110"},{"groupId":"OG001","value":"0.24","spread":"0.077"},{"groupId":"OG002","value":"0.45","spread":"0.077"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 96 in Part B","description":"The BASDAI is a validated self-reported instrument, which consists of six 10 unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI scores ranges from 0 to 10, with lower scores indicating lower disease activity.\n\nThe change from Part B Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"0.226"},{"groupId":"OG001","value":"0.56","spread":"0.176"},{"groupId":"OG002","value":"0.78","spread":"0.176"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 96 in Part B","description":"The BASFI is a validated disease-specific instrument for assessing physical function. The BASFI comprises 10 items relating to the past week. The BASFI is the mean of the 10 scores such that the total score ranges from 0 (Easy) to 10 (Impossible), with lower scores indicating better physical function.\n\nThe change from Part B Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":"0.233"},{"groupId":"OG001","value":"0.32","spread":"0.198"},{"groupId":"OG002","value":"0.46","spread":"0.205"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 96 in Part B","description":"The BASMI is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the sum of the 5 scores provided the total BASMI score, ranging from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their axial spondyloarthritis (axSpA).\n\nThe change from Part B Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.105"},{"groupId":"OG001","value":"0.00","spread":"0.065"},{"groupId":"OG002","value":"-0.03","spread":"0.068"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response Criteria Response at Week 96 in Part B","description":"The BASDAI50 response was defined as an improvement of at least 50 % in the BASDAI score relative to Baseline.\n\nMissing data were handled using non-response imputation (NRI) methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"83.7","spread":null},{"groupId":"OG002","value":"77.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sacroiliac Spondyloarthritis Research Consortium of Canada (SPARCC) Score at Week 96 in Part B","description":"The SPARCC scoring method for lesions found on the Magnetic Resonance Imaging (MRI) is based on an abnormal increased signal on the Short-Tau-Inversion Recovery (STIR) sequence, representing bone marrow edema. Total Sacroiliac (SI) joint SPARCC score can range from 0 to 72 with higher scores indicating higher joint inflammation.\n\nThe change from Part B Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"3.6"},{"groupId":"OG001","value":"0.2","spread":"2.4"},{"groupId":"OG002","value":"0.6","spread":"3.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Spine Ankylosing Spondylitis Spine Magnetic Resonance Imaging Score for Disease Activity (ASspIMRI-a) in the Berlin Modification Score at Week 96 in Part B","description":"The Berlin modification of the ASspiMRI-a is a scoring system with a concentration on Short-Tau-Inversion Recovery (STIR) sequences without other fat saturation techniques. It quantifies changes in 23 Vertebral Units (VU) of the spine. Active inflammation was scored by grading the degree of bone marrow edema from 0 to 3 in 1 dimension on 1 or more consecutive slices that represent the highest level of inflammation in a particular VU.\n\nThe change from Part B Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.9"},{"groupId":"OG001","value":"0.0","spread":"0.8"},{"groupId":"OG002","value":"0.0","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) Disease Activity Categories at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nDisease activity was measured by categorical response variables:\n\n* ASDAS-Inactive Disease (ASDAS-ID): ASDAS \\< 1.3\n* ASDAS-Moderate Disease (ASDAS-MD): ASDAS ≥ 1.3, \\< 2.1\n* ASDAS-High Disease activity (ASDAS-HD): ASDAS ≥ 2.1, ≤ 3.5\n* ASDAS-very High Disease activity (ASDAS-vHD): ASDAS \\> 3.5","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Ankylosing Spondylitis Disease Activity Score (ASDAS) Clinical Improvement Categories at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nASDAS improvement was measured by binary response variables:\n\n* ASDAS-CII: ASDAS reduction (improvement) of ≥ 1.1 relative to Baseline\n* ASDAS-MI: ASDAS reduction (improvement) of ≥ 2.0 relative to Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"13.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society 20 % Response Criteria (ASAS20) Response at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The ASAS20 response was defined as an improvement of at least 20 % and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA), Pain assessment (total spinal pain NRS scores), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) and absence of deterioration in the potential remaining domain \\[deterioration was defined as a relative worsening of at least 20% and an absolute worsening of at least 1 unit\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"64.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society 40 % Response Criteria (ASAS40) Response at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The ASAS40 response was defined as a relative improvement of at least 40 % and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA), Pain assessment (total spinal pain NRS scores), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) and no worsening at all in the remaining domain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society (ASAS) 5/6 Response Criteria Response at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The ASAS 5/6 response was defined as achieving at least 20 % improvement in 5 of 6 domains, including the 4 domains defined for ASAS20 as well as spinal mobility (lateral spinal flexion) and C-reactive Protein (CRP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Axial SpondyloArthritis International Society (ASAS) Partial Remission (PR) Response Criteria Response at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The ASAS partial remission (PR) response was defined as a score of ≤ 2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS20.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The ASDAS was calculated as the sum of the following components:\n\n0.121 x Back pain (BASDAI Q2 result) 0.058 x Duration of morning stiffness (BASDAI Q6 result) 0.110 x PGADA (Patient's Global Assessment of Disease Activity) 0.073 x Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm \\[ln\\] of the (CRP \\[mg/L\\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units).\n\nThere is a minimum score of 0.636 for the total ASDAS score, but no defined upper score. Based on the formula even in the situation that the CRP is normal, any value below 4 is recorded as \"below the limit of quantification\" (BLQ) and a value of BLQ/2=2 was prespecified. This assumption is triggering the lowest possible value of 0.636.\n\nThe change from Part B Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.18","spread":"1.13"},{"groupId":"OG001","value":"-0.56","spread":"0.64"},{"groupId":"OG002","value":"-0.83","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The BASDAI is a validated self-reported instrument, which consists of six 10 unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI scores ranges from 0 to 10, with lower scores indicating lower disease activity.\n\nThe change from flare Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.75","spread":"2.52"},{"groupId":"OG001","value":"-1.55","spread":"1.05"},{"groupId":"OG002","value":"-2.29","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The BASFI is a validated disease-specific instrument for assessing physical function. The BASFI comprises 10 items relating to the past week. The BASFI is the mean of the 10 scores such that the total score ranges from 0 (Easy) to 10 (Impossible), with lower scores indicating better physical function.\n\nThe change from flare Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.52","spread":"2.46"},{"groupId":"OG001","value":"-0.72","spread":"0.70"},{"groupId":"OG002","value":"-1.83","spread":"2.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The BASMI is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the sum of the 5 scores provided the total BASMI score, ranging from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their axial spondyloarthritis (axSpA).\n\nThe change from flare Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.58"},{"groupId":"OG001","value":"-0.27","spread":"0.35"},{"groupId":"OG002","value":"-0.26","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sacroiliac Spondyloarthritis Research Consortium of Canada (SPARCC) Score at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The SPARCC scoring method for lesions found on the Magnetic Resonance Imaging (MRI) is based on an abnormal increased signal on the Short-Tau-Inversion Recovery (STIR) sequence, representing bone marrow edema. Total Sacroiliac (SI) joint SPARCC score can range from 0 to 72 with higher scores indicating higher joint inflammation.\n\nThe change from flare Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"13.2"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"0.2","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Spine Ankylosing Spondylitis Spine Magnetic Resonance Imaging Score for Activity (ASspIMRI-a) in the Berlin Modification Score at Escape Week 12 for Participants Who Experienced a Flare in Part B","description":"The Berlin modification of the ASspiMRI-a is a scoring system with a concentration on Short-Tau-Inversion Recovery (STIR) sequences without other fat saturation techniques. It quantifies changes in 23 Vertebral Units (VU) of the spine. Active inflammation was scored by grading the degree of bone marrow edema from 0 to 3 in 1 dimension on 1 or more consecutive slices that represent the highest level of inflammation in a particular VU.\n\nThe change from flare Baseline is calculated, a negative value indicating improvement and a positive value worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"4.6"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"-0.3","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Certolizumab Pegol (CZP) Plasma Concentration During the Study","description":"CZP plasma concentration was measured in micrograms per milliliter (μg/mL). Blood sample measurements that were deemed to be below the level of quantification, were set to half the lower level of quantification (LLOQ) for analysis purposes. Summary statistics were only displayed if at least two-thirds of the values were above the LLOQ and if n was greater or equal to (\\>=) 4.\n\nThe primary purpose of the study was to evaluate treatment options for axSpA patients after being in sustained remission. Hence, one of the objectives was to evaluate the PK of these patients. The CZP plasma concentration of the patients that did not reach sustained remission were therefore not analysed, and the Pharmacokinetic Set A as described in the protocol was removed from the SAP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.71","spread":"85.76"},{"groupId":"OG001","value":"53.39","spread":"30.93"},{"groupId":"OG002","value":"48.92","spread":"43.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.91","spread":"89.23"},{"groupId":"OG001","value":"31.74","spread":"50.79"},{"groupId":"OG002","value":"30.69","spread":"56.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.31","spread":"135.58"},{"groupId":"OG001","value":"30.23","spread":"46.57"},{"groupId":"OG002","value":"28.96","spread":"58.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.28","spread":"74.18"},{"groupId":"OG001","value":"36.59","spread":"84.36"},{"groupId":"OG002","value":"31.11","spread":"138.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"27.76","spread":"49.47"},{"groupId":"OG002","value":"6.95","spread":"178.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"26.36","spread":"105.58"},{"groupId":"OG002","value":"7.61","spread":"176.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"26.57","spread":"44.90"},{"groupId":"OG002","value":"8.00","spread":"113.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"24.76","spread":"97.60"},{"groupId":"OG002","value":"7.16","spread":"131.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"1802.40"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"0.30","spread":"2621.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"30.77","spread":"19.78"},{"groupId":"OG002","value":"12.70","spread":"98.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.27","spread":"488.45"},{"groupId":"OG001","value":"33.50","spread":"21.17"},{"groupId":"OG002","value":"15.43","spread":"124.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.32","spread":"151.18"},{"groupId":"OG001","value":"32.94","spread":"30.48"},{"groupId":"OG002","value":"18.43","spread":"79.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.89","spread":"232.36"},{"groupId":"OG001","value":"23.76","spread":"65.42"},{"groupId":"OG002","value":"19.14","spread":"136.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.47","spread":"45.31"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"19.23","spread":"66.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.88","spread":"77.53"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.64","spread":"112.75"},{"groupId":"OG001","value":"26.19","spread":"54.74"},{"groupId":"OG002","value":"18.59","spread":"95.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"133329.3"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"0.52","spread":"1158.85"},{"groupId":"OG002","value":"0.14","spread":"772.54"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Positive Anti-certolizumab Pegol-antibody Levels in Plasma During the Study","description":"Treatment emergent ADAb status positive was defined as either baseline ADAb negative subjects having at least one ADAb confirmed positive sample post baseline or baseline ADAb positive subjects with at least one post baseline sample with \\>= minimum significant ratio (MSR) increase from baseline on CZP treatment. Once determined positive, the highest titer during Part A and Part B (including Escape and Safety Follow up) was used to categorize the subject.\n\nThe primary purpose of the study was to evaluate treatment options for axSpA patients after being in sustained remission. Hence, one of the objectives was to evaluate the immunogenicity of these patients. The ADAb titer of the patients that did not reach sustained remission were therefore not analysed, and the Pharmacokinetic Set A as described in the protocol was removed from the SAP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.1","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Adverse Event (AE) During Part A of the Study","description":"An AE was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Adverse Event (AE) During Part B of the Study","description":"An AE was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.\n\nFor subjects with flare in Part B and do escape to CZP full-dose therapy, only TEAEs with an onset date prior to the start date of escape CZP full-dose therapy were included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":null},{"groupId":"OG001","value":"57.7","spread":null},{"groupId":"OG002","value":"61.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Adverse Event (AE) and Who Experienced a Flare During Part B of the Study","description":"An AE was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.\n\nFor subjects with flare in Part B and do escape to CZP full-dose therapy, only TEAEs with an onset date after or on the start date of escape CZP full-dose therapy were included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":44,"n":736},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Pharyngitis","Bronchitis","Axial spondyloarthritis"]}}}